Description:
Ponatinib hydrochloride is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. It has potential antiangiogenic and antineoplastic activities. It inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. It inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). It was developed by Ariad Pharm and has been listed.
- Molecular Weight:569.03
- Purity:>98%
Molecular Formula:
C29H28ClF3N6O
Canonical SMILES:
O=C(NC1=CC=C(CN2CCN(C)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(C#CC4=CN=C5C=CC=NN54)=C3.[H]Cl
InChI:
1S/C29H27F3N6O.ClH/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37;/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39);1H
InChIKey:
BWTNNZPNKQIADY-UHFFFAOYSA-N
Solubility:
10 mM in DMSO
Appearance:
Solid powder
Application:
Ponatinib hydrochloride is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). It has potential antiangiogenic and antineoplastic activities.
Storage: -20°C Freezer
Synonyms:
3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide hydrochloride; AP24534; AP-24534; AP 24534; Ponatinib HCl; Ponatinib hydrochloride trade name Iclusig Más detalles se encuentran
aquí